Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Indirect comparison of continuous and time‑limited BTKi-venetoclax in TP53‑wild‑type CLL: does IGHV still matter? | Leuk Lymphoma | 2026 | 41779428 | PubTator, text mining | PubMed |
| Richter transformation to classical Hodgkin lymphoma following recurrent disseminated histoplasmosis in chronic lymphocytic leukemia: a Case Report. | Front Oncol | 2026 | 41777646 | PubTator, text mining | PubMed |
| The Complexity of Immunoglobulin A Immune Responses in Respiratory Syncytial Virus Infection. | Viruses | 2026 | 41754493 | PubTator, text mining | PubMed |
| Efficacy and Long-Term Remission Following Haploidentical HSCT for Therapy-Related Acute Myelomonocytic Leukemia with Plasmacytoid Dendritic Cells Post-FCR Therapy for CLL: A Case Report. | J Clin Med | 2026 | 41753246 | PubTator, text mining | PubMed |
| Evaluation of mTOR, NFκB, and BCL-2 Inhibitor Activity In Vitro on Diffuse Large B-Cell Lymphoma Cells. | Curr Issues Mol Biol | 2026 | 41751491 | PubTator, text mining | PubMed |
| Is CLL curable? | Hemasphere | 2026 | 41743268 | PubTator, text mining | PubMed |
| When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia. | Curr Hematol Malig Rep | 2026 | 41741806 | PubTator, text mining | PubMed |
| Cost-Effectiveness of Venetoclax-Based Treatment in Treatment-Naïve Fit Patients With CLL Without TP53 Aberrations. | Eur J Haematol | 2026 | 41740591 | PubTator, text mining | PubMed |
| Unveiling the Genetic and Immunophenotypic Landscape of Chronic Lymphocytic Leukemia in Indian Cohort. | Indian J Hematol Blood Transfus | 2026 | 41728154 | PubTator, text mining | PubMed |
| WWC proteins as emerging biomarkers and therapeutic targets in cancer pathogenesis. | Front Cell Dev Biol | 2026 | 41727322 | PubTator, text mining | PubMed |
| Pseudo-Richter Transformation Following BTKi Interruption in CLL: A Systematic Review of Clinical, Biological, and Pathologic Features. | Clin Lymphoma Myeloma Leuk | 2026 | 41720666 | PubTator, text mining | PubMed |
| Post-treatment infection prediction in CLL using domain adaptation of lymphoma electronic health records. | Acta Oncol | 2026 | 41711490 | PubTator, text mining | PubMed |
| Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation. | Hemasphere | 2026 | 41704549 | PubTator, text mining | PubMed |
| Real-world disease characteristics and frontline treatments used in chronic lymphocytic leukaemia in Bulgaria: An observational cohort study (DESCRIBE). | J Int Med Res | 2026 | 41698655 | PubTator, text mining | PubMed |
| Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study. | Blood Cancer Discov | 2026 | 41678768 | PubTator, text mining | PubMed |
| Altered B cell activation contributes to the immunopathogenesis of childhood arthritis-associated uveitis. | Nat Commun | 2026 | 41633998 | PubTator, text mining | PubMed |
| Correction to "Risk scores predicting disease progression in early-stage chronic lymphocytic leukemia: comparative analysis and usefulness of IGHV subset #2 to improve their accuracy". | Cancer | 2026 | 41632040 | PubTator, text mining | PubMed |
| TP53-aberrated CLL: is BTK inhibitor monotherapy enough? | Blood Adv | 2026 | 41615766 | PubTator, text mining | PubMed |
| Triplet regimens for frontline treatment of CLL-Great company or just a crowd? | Hemasphere | 2026 | 41560849 | PubTator, text mining | PubMed |
| Can minimal residual disease be used to tailor therapy duration for chronic lymphocytic leukemia patients? | Expert Rev Hematol | 2026 | 41548072 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=3